The Readout LOUD

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come. Subscribe today on iTunes, SoundCloud, and Stitcher.

The Readout LOUD

LISTEN: Founders’ funds, doctors’ disclosures, and the subtle art of beeping

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: A genome-editing flop, a Celgene Senate hopeful, and a live audience

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: FDA shows its teeth, biotech fish oil might be pointless, & the quest to cure McCain’s cancer

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A genome-editing first, Trump on Wall Street, and biotech red flags

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: A lesson in startup jargon, pharma’s bare Alzheimer’s cupboard, and the cost of CAR-T

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Insider trading goes to Washington, online bloodshed over fake meat, & doctors vs. fund managers

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: Biotech’s sellers market, Sanofi’s second act, and literally climbing Mt. Everest

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A debatable Alzheimer’s breakthrough, Gilead’s golden age, and separating smart money from dumb

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Pharma at the midterms, CRISPR’s latest crack-up, and your guide to earnings

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Trump’s telephonic prowess, Biogen’s mysterious future, & the rise of ‘hypelines’

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Biotech’s six months of surprise, the shaky road ahead, and sell-side self-doubt

By Damian Garde and Adam Feuerstein

The Readout LOUD

LISTEN: A friendly FDA, divided drug lobbyists, and 23andMexico

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Sarepta’s gene therapy coup, Theranos’ legal defense, and parsing hype in AI

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Problematic parties, NASH nitpicks, and an intimate look at the opioid crisis

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Twitter vitriol, biotech jargon, and the plight of the CEO

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Why fatty livers are a pharma goldmine, a guide to ASCO and BIO, and Trump’s latest drug price promise

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: World Cup genetics, the latest Ebola outbreak, and how to fix drug pricing

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Inside the Theranos collapse, Valeant’s latest legal lumps, and a bunch of biotech hot takes

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Novartis’ bad day, Spark’s Amish entanglement, and a biotech history lesson

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Chinese biotech bubbles, activist investors, & Bill Gates’s flu frugality

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Megamergers, migraines, and biotech’s Four Horsemen

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: The Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: Biotech buyouts, CEO breakups, and The Rock does CRISPR

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: The FDA’s cold shoulder, the latest CAR-T contender, and how Grindr relates to personal genetics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A billionaire intervenes, inscrutable drug prices, and no grade inflation for biotechs

By Rebecca Robbins and Adam Feuerstein

The Readout LOUD

LISTEN: An eyewitness gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Shkreli’s sentence, biotech froth, and a blood party

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

Biotech

Introducing a new biotech podcast from STAT

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

« Previous Page

The Readout LOUD

Sign up for our Daily Recap newsletter